Overview

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Status:
Recruiting

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

This phase III trial aims to compare the efficacy and safety of fulvestrant or capecitabine as maintenance therapy after first-line chemotherapy in hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Herui Yao

Collaborators:

First Affiliated Hospital, Sun Yat-Sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangdong Provincial People's Hospital
Peking University Shenzhen Hospital
Sun Yat-sen University

Treatments:

Capecitabine
Fulvestrant